Gosset Ownership
Private
Employees
~6
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Haoma Medica General Information
Haoma Medica has developed NaQuinate, a novel small molecule compound for osteoporosis and osteopenia. The first-in-human Phase I study demonstrated safety, tolerability, and pharmacokinetics in healthy volunteers. The compound works by regulating both bone formation and resorption with the potential for long-term use due to its natural occurrence in the body. No efficacy data from later-stage trials are yet available.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
London, England
United Kingdom
United Kingdom
Drug Pipeline
naquinate
Phase 2Key Partnerships
Haoma Medica Funding
No funding data available
To view Haoma Medica's complete valuation and funding history, request access »